Previous cytotoxin patients thought they were on placebo during atezolizumab trial due to low toxicity side effects
Fadi Braiteh, MD Comprehensive Cancer Centers of Nevada discusses Previous cytotoxin patients thought they were on placebo during atezolizumab trial due to low toxicity side effects
Author: ASCO2016
Added: 06/28/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 28, 2016 Category: Cancer & Oncology Source Type: podcasts
EHA 2016: Side effects of novel drugs and managing patient expectations in CLL
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses the side effects of novel drugs in chronic lymphocytic leukemia (CLL). According to Dr Ghia, the toxicity profile...
Author: VJHemOnc
Added: 06/21/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2016 Category: Cancer & Oncology Source Type: podcasts
Many compounds are being combined with immunotherapy drugs due to their low toxicity
Alexander Spira, MD of Virginia Cancer Specialist remarks on the many different combinations of immunotherapy drugs that are being being tested due to the low toxicity of these drugs
Author: ASCO2016
Added: 06/16/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 16, 2016 Category: Cancer & Oncology Source Type: podcasts
Renal complications in multiple myeloma - characteristics and treatment
Nelson Leung, MD from the Mayo Clinic, Rochester, MN gives an overview of the common kidney problems in multiple myeloma (MM). The proteins produced by the myeloma cells are toxic to the kidney in var...
Author: VJHemOnc
Added: 06/14/2016 (Source: Oncology Tube)
Source: Oncology Tube - June 14, 2016 Category: Cancer & Oncology Source Type: podcasts
Understanding Targeted Research for Head and Neck Cancers
What are the targeted and less toxic treatments for head and neck cancers? Patient Power Founder and Host, Andrew Schorr, interviews Head and Neck Oncologist, Dr. Faye Johnson of The University of Tex...
Author: P2Professional
Added: 05/18/2016 (Source: Oncology Tube)
Source: Oncology Tube - May 19, 2016 Category: Cancer & Oncology Source Type: podcasts
Understanding Targeted Research for Head and Neck Cancers
What are the targeted and less toxic treatments for head and neck cancers? Patient Power Founder and Host, Andrew Schorr, interviews Head and Neck Oncologist, Dr. Faye Johnson of The University of Tex...
Author: patientpower
Added: 05/16/2016 (Source: Oncology Tube)
Source: Oncology Tube - May 17, 2016 Category: Cancer & Oncology Source Type: podcasts
Are There Clinically Significant Distinctions Between PD-1 and PD-L1?
Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.
http://cancergrace.org/lung..._...
Author: cancergrace
Added: 04/20/2016 (Source: Oncology Tube)
Source: Oncology Tube - April 20, 2016 Category: Cancer & Oncology Source Type: podcasts
Toxicities of anti-PD-1 and anti-PD-L1 in gynecologic cancers #SGOmtg
Michael J. Birrer, MD of Dana-Farber discusses toxicities of anti-PD-1 and anti-PD-L1 in gynecologic cancers at SGO 2016.
Author: sgo2016
Added: 03/23/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 23, 2016 Category: Cancer & Oncology Source Type: podcasts
Balancing drug affordability and care for cancer patients
Progress in the field of blood cancers has resulted in the rapid development of more effective, less toxic therapies. At the German Cancer Congress 2016, held in Berlin, Germany from 24 February to 27...
Author: VJHemOnc
Added: 03/04/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 4, 2016 Category: Cancer & Oncology Source Type: podcasts
The balance between drug affordability and cancer care
Progress in the field of blood cancers has resulted in the rapid development of more effective, less toxic therapies. At the German Cancer Congress 2016, held in Berlin, Germany, from 24 February to 2...
Author: VJHemOnc
Added: 03/04/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 4, 2016 Category: Cancer & Oncology Source Type: podcasts
Discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC #GU16
Guillermo De Velasco, MD at Dana Farber discusses discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC
at ASCO GU 2016
Author: 2016_Genitourinary
Added: 03/03/2016 (Source: Oncology Tube)
Source: Oncology Tube - March 3, 2016 Category: Cancer & Oncology Source Type: podcasts
TAS-102 mechanism of action and potential toxicity in advanced CRC
Eric Van Cutsem, MD of University of Leuven discusses the TAS-102 mechanism of action and potential toxicity in advanced CRC
Author: ASCOGI2016
Added: 01/29/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 29, 2016 Category: Cancer & Oncology Source Type: podcasts
Managing Immunotherapy Side Effects
Dr. Evan J. Lipson, Johns Hopkins University, discusses the incidence and treatment of side effects of immunotherapy and compares them to chemotherapy toxicities.
http://cancergrace.org/canc......
Author: cancergrace
Added: 01/15/2016 (Source: Oncology Tube)
Source: Oncology Tube - January 15, 2016 Category: Cancer & Oncology Source Type: podcasts
Idelalisib + Rituximab Successful in Frontline with Some Toxicity
Susan M. O’Brien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine discusses how Idelalisib + Rituximab is Successful in Frontline but with Some ...
Author: ASHReport
Added: 12/10/2015 (Source: Oncology Tube)
Source: Oncology Tube - December 10, 2015 Category: Cancer & Oncology Source Type: podcasts
